Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tilavonemab - AbbVie/C2N Diagnostics

Next Previous
Search
Drug Profile

Tilavonemab - AbbVie/C2N Diagnostics

Alternative Names: ABBV-8E12; C2N-8E12

Latest Information Update: 27 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator C2N Diagnostics
  • Developer AbbVie; C2N Diagnostics
  • Class Antibodies; Antiparkinsonians; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progressive supranuclear palsy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Discontinued Progressive supranuclear palsy

Most Recent Events

  • 28 Jul 2024 Efficacy data from a phase II trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)
  • 30 Sep 2021 AbbVie completes phase II clinical trials in Alzheimer's disease (Early-stage disease) the US, Australia, Belgium, Canada, New Zealand and Sweden (IV) in September 2021 (NCT03712787) (EudraCT2018-000268-26)
  • 05 Jul 2021 AbbVie completes phase II clinical trials in Alzheimer's disease (Early-stage disease) in the US, Australia, Belgium, Canada, Denmark, Finland, Italy, New Zealand, Netherland, Sweden and Spain (IV) (NCT02880956)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top